1. Introduction
===============

Natriuretic peptides constitute a family of three structurally related molecules: atrial natriuretic peptide (ANP) [@B1], brain natriuretic peptide (BNP) [@B2], and C-type natriuretic peptide (CNP) [@B3]. ANP and BNP act mainly as cardiac hormones and are produced primarily by the atria and ventricles, respectively, whereas C-type natriuretic peptide is expressed mainly in the brain [@B4],[@B5].

BNP, which was originally isolated from the porcine brain [@B6], shows an amino acid sequence homology to ANP. BNP has central and peripheral actions that are similar to those of ANP. The heart has the highest concentrations of BNP, and BNP acts as a cardiac hormone. Intravenous injection of BNP causes a significant decrease in blood pressure [@B7]. Transgenic mice that overexpress BNP have a measurable reduction in blood pressure [@B8]. Mukoyama *et al.* showed that plasma BNP levels are higher in individuals with essential hypertension (EH) than in normotensive (NT) individuals [@B7]. These findings suggest that the BNP gene is a candidate gene for EH. EH is thought to be a multifactorial disorder; several studies have shown that an association analysis with genetic variants can be used to identify susceptibility genes for EH [@B9].

The aim of the present study was to identify mutations or polymorphisms in the 5\'-flanking region of the *NPPB* gene and to assess the relationship between variants of the gene and EH.

2. Subjects and Methods
=======================

Subjects
--------

The EH group consisted of 317 patients (mean age, 49.7 ± 7.8 years) with EH diagnosed based on sitting systolic blood pressure (SBP) greater than 160 mmHg and/or diastolic blood pressure (DBP) greater than 100 mmHg measured on three separate occasions within 2 months after the initial BP measurement (Table [1](#T1){ref-type="table"}). These patients were not being treated with antihypertensive drugs. All EH subjects had a positive family history of hypertension; patients diagnosed with secondary hypertension were excluded from the study. We also enrolled 262 healthy, normotensive (NT) subjects (mean age, 51.2 ± 10.8 years). None of the NT subjects had a family history of hypertension; all had an SBP less than 130 mmHg and a DBP less than 85 mmHg. A family history of hypertension was defined as having grandparents, uncles, aunts, parents, or siblings who had been diagnosed with hypertension. Written informed consent was obtained from each subject based on a protocol approved by the Ethics Committee of the Nihon University School of Medicine and the Clinical Studies Committee of Nihon University Hospital [@B10].

Biochemical analysis
--------------------

Plasma total cholesterol concentrations, as well as serum creatinine and uric acid concentrations, were measured using standard methods in the Clinical Laboratory Department of Nihon University Hospital [@B11]. Plasma BNP levels were measured in NT subjects and EH patients. A total of 76 subjects (43 in the NT group and 33 in the EH group) who did or did not have the 16 repeat allele were selected randomly. Plasma BNP levels were measured using a highly sensitive immunoradiometric assay (Shiono RIA BNP assay kit, Shionogi Co., Ltd., Tokyo, Japan) as described previously [@B12].

Polymerase chain reaction - single strand conformation polymorphism (PCR-SSCP)
------------------------------------------------------------------------------

Genomic DNA was extracted from peripheral blood leukocytes using a standard method [@B13]. To screen for mutations, two oligonucleotide primers (sense, 5\'- AAGGAGGCACTGGGAGAGGGGAAAT -3\' (bases -1323 to -1299 from the major transcriptional initiation site) and antisense, 5\'-AATTAGCTGGGCATGGTGGCAGGCG-3\' (bases -1075 to -1051)) that recognize part of the 5\'-flanking region of the *NPPB* gene were designed, since this region has been reported to be a major promoter region (Fig. [1](#F1){ref-type="fig"}A) [@B14]. PCR-SSCP was done (GenePhor System; Amersham Biosciences Corp, Piscataway, NJ, USA) [@B15]. PCR was performed using a GeneAmp PCR system 9700 (Applied Biosystems, Branchburg, NJ, USA) with the following amplification conditions: initial denaturation at 96^°^C for 3 min followed by 35 cycles of 98.5^°^C for 25 s, 65^°^C for 30 s, 68^°^C for 30 s, and a final extension of 68^°^C for 10 min. PCR products were separated by electrophoresis on 10% precast polyacrylamide gels (Amersham Biosciences Corp) at 5^°^C for 80 min and then subjected to silver staining (Dai-ichi Kagaku, Tokyo, Japan). The electrophoresis parameters were set according to the manufacturer\'s protocol.

Sequencing analysis
-------------------

Two oligonucleotides (sense, 5\'-AAGGAGGCACTGGGAGAGGGGAAAT-3\' (bases -1323 to -1299) and antisense, 5\'- CCCCACCAAGCCAACACAGGATGGA -3\' (bases -919 to-895) were used to amplify a 429-bp product from genomic DNA (Fig. [1](#F1){ref-type="fig"}A). The PCR products were purified using a Microcon 100 column (U.S. Amicon Inc. Beverly, MA,USA). The resulting products were ligated to pCR2.1^TM^ vectors and cloned (TA Cloning Kit, Invitrogen, San Diego, CA, USA). The ligation of the products was confirmed by direct DNA sequencing (ABI PRISM 310 Genetic Analyzer) [@B16].

Genotyping
----------

Genotyping was done using fragment analysis, and the sequencing primers were used. PCR amplification consisted of an initial denaturation at 94^°^C for 3 min, followed by 35 cycles of 98.5^°^C for 25 sec, 63^°^C for 30 s, 72^°^C for 1 min, and a final extension of 72^°^C for 10 min. Then, the PCR products were analyzed using an automatic electrophoresis system (Agilent 2100 bioanalyzer system^TM^; Agilent Technologies, Waldbronn, Germany).

Statistical analysis
--------------------

Data are presented as the mean ± SD. The Hardy-Weinberg equilibrium was assessed by doing chi-square (χ^2^) analysis. Differences in the clinical data between the EH and NT groups were assessed by analysis of variance (ANOVA). The distributions of the genotypes or alleles between EH patients and NT subjects were tested using a two-sided Fisher\'s exact test. Multiple logistic regression analyses were done to assess the contribution of confounders (gender, BMI) [@B17]. A value of *P* \< 0.05 was considered statistically significant.

3. Results
==========

We discovered a novel variable number of tandem repeat (VNTR) polymorphism consisting of a 11-nucleotide repeat of 4 base pairs (bp) in the 5\'-flanking region (-1241 nucleotides from the major transcriptional initiation site) (GenBank accession number AB265677). This VNTR polymorphism is a tandem repeat of the 4-nucleotide sequence TTTC (Fig. [1](#F1){ref-type="fig"}A). There were 8 alleles of this VNTR polymorphism, ranging from 9-repeat to 19-repeat (Fig. [1](#F1){ref-type="fig"}B).

The association study showed that the 11-repeat allele was most frequent in the NT group (88.2%). The 16-repeat allele was second most frequent in the NT group (10.5%). Furthermore, in the NT group, the observed and expected genotypes were in good agreement with the predicted Hardy-Weinberg equilibrium values (P=0.972). Of note, the overall distribution of genotypes in females was significantly different between the EH and NT groups (p=0.039); the frequency of the 16-repeat allele was significantly lower in the EH group (6.5%) than in the NT group (12.2%, p=0.046) (Table [2](#T2){ref-type="table"}).

On multiple logistic regression analysis, a significant association between allele 16 (p=0.034) and female gender was noted, even after adjustment for confounding factors; the calculated odds ratio was 1.18 (95%CI: 1.07-1.20).

The clinical data of each genotype were assessed. There were no significant differences in SBP and DBP levels, or in the pulse of subjects with or without the 16 repeat allele (Table [3](#T3){ref-type="table"}).

The plasma BNP level was significantly higher in the EH group than in the NT group (p=0.0203). The plasma BNP level in each genotype with or without the 16 repeat allele was determined (Table [4](#T4){ref-type="table"}); there were no significant differences among the groups. It was impossible to perform this analysis in EH females, as none of them had the 16 repeat allele.

All subjects were classified into 3 groups based on their BMI levels (lean, BMI\<18.5; normal, 18.5\<BMI\<25; obese, BMI \>25). There was no association between the genotype and the BMI among the groups (Table [5](#T5){ref-type="table"}).

4. Discussion
=============

Ogawa *et al.*reported that the 5\'-flanking region of the 1.9 kilo-base pairs in the *NPPB* gene has a high transcriptional activity. Using the deletion mutant model, the deletion of sequences between -1288 and -1095 reduced transcriptional activity to approximately 30%. These deleted sequences contain a characteristic CT-rich region (-1248 to -1191), followed by an Alu family sequence (-1190 to -934). Thus, these results are consistent with the hypothesis that Alu repeat sequences in the 5\'-flanking regions have regulatory roles in *NPPB* expression [@B14]. Therefore, we assessed the association between mutations or polymorphisms in the 5\'-flanking region of *NPPB* and the presence of EH. In the present study, a novel VNTR was discovered, and a significant association between the VNTR and EH was found in female patients. The present study found that the number of patients with a 16 repeat allele of VNTR was lower in EH women than in NT women. It is well known that the plasma BNP level is higher in EH patients than in NT subjects, since an elevated blood pressure results in a high plasma BNP level, which is one of the protective factors for hypertension [@B4]. We compared the plasma BNP levels of patients with and without the 16 repeat allele and found that there was no significant difference between the two groups. In fact, there were not enough subjects to allow the association studies to be done by gender. Given our results, these limitations should be addressed in future studies. It is possible that factors other than the *NPPB* gene may have affected the BNP levels, since many factors, including cardiac function and blood pressure, are known to affect human plasma BNP levels. Thus, it is possible that the plasma BNP level is not an accurate reflection of the function of the *NPPB* gene.

In the present study, the overall distribution of the VNTR genotype and the allele frequency were significantly different in females but not in males. Gender-specific susceptibility to EH is an interesting finding, but its importance is still unclear [@B11]. Redfield*et al*. reported that BNP levels increased with age, and were higher in females than males among subjects with no known cardiovascular or detectable structural heart disease [@B18]. Maffei*et al*. reported that hormone replacement therapy increased BNP levels in postmenopausal women [@B19]. Although the absolute BNP value was different between these two studies, which used two different assays, the associations of the BNP levels with age and gender were consistent. Furthermore, the BNP level that had the optimal sensitivity and specificity for detecting systolic dysfunction in the overall population increased with age and was higher in women. This underscores the clinical relevance of the relationship of age, gender, and BNP. In both studies that used different assays, the effect of gender on BNP was substantial and independent of other factors [@B18]. Unfortunately, we were not able to obtain samples to measure plasma BNP and ANP levels, due to the difficulty in obtaining written informed consent for blood examinations from subjects not receiving medications.

In the Japanese population, it has been reported that plasma BNP levels are positively associated with age, urinary salt excretion, higher blood pressure, a high R-wave voltage in the 12-lead ECG (Code 3-1 or 3-3), and female gender [@B20],[@B21]. On the other hand, Freitag*et al*., based on multivariate models adjusting for known risk factors, showed that elevated plasma BNP levels were associated with an increased risk of blood pressure progression in males but not in females. However, there was no significant trend of an increasing incidence of hypertension among BNP categories in either males or females. In a community-based sample, higher plasma BNP levels were found to be associated with an increased risk of BP progression in males, but not in females [@B22]. Further studies are needed to resolve these conflicting results.

Since there are many loci with a high degree of polymorphism in the number of tandemly repeated nucleotide sequence units, VNTR polymorphisms, also called minisatellites, were originally studied for linkage-mapping purposes. VNTRs have a highly polymorphic nature that makes them very useful as markers, both in linkage studies to map disease loci in families and in forensic applications. Recent reports indicate that some VNTR sequences may function as transcriptional or translational regulators, and that they may modify the function of a protein when the tandemly repeated region lies within the coding region of the gene [@B23]. Although no clear effect on transcription has been shown, it has been reported that a VNTR in the second intron of the serotonin transporter gene is associated with susceptibility to major depression [@B24].

We previously determined the structural organization of human natriuretic peptide receptor genes [@B25]-[@B28] and identified an insertion/deletion mutation in the 5\'-untranslated region of NPRA [@B12]. The deletion encompasses eight nucleotides and alters the binding sites for the AP2 and zeste transcription factors. Transcriptional activity of the deletion allele was less than 30% that of the wild-type allele. The deletion allele was significantly more common in the EH group than in the NT group. These findings suggest that in Japanese individuals, this deletion in the NPRA gene reduces receptor activity and may confer increased susceptibility for the individual to develop EH or left ventricular hypertrophy (LVH). Animal models with a deletion of this gene develop disorders that resemble the symptoms of subjects with a deleted allele in the 5\'-untranslated region of NPRA. We previously isolated a missense mutation of the NPRA gene [@B29] and a VNTR polymorphism upstream of the NPRC gene; this VNTR influences blood pressure levels in obesity-associated hypertension [@B30]. Since the sampling of the above reports was different from the present experiment, it was impossible to analyze the relationship between systemic natriuretic peptide genes and EH.

Wang *et al.* reported that obese individuals have low circulating natriuretic peptide levels, which may contribute to their susceptibility to hypertension and hypertension-related disorders. The mechanisms linking obesity to hypertension have not been established, but sodium retention and excessive sympathetic tone are key contributors. Natriuretic peptides are important regulators of sodium homeostasis and neurohormonal activation; this raises the possibility that obese individuals have an impaired natriuretic peptide response [@B31]. Therefore, we examined the relationship between the genotype and BMI and found no significant association.

In conclusion, a novel VNTR in the 5\'-flanking region of the *NPPB* gene was discovered. This polymorphism was associated with EH in female subjects. However, this finding does not necessarily imply that there is a relationship between the *NPPB* gene and EH. Further studies of other polymorphisms are needed to determine whether there is an association between the *NPPB* gene and EH.
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![**A**: Nucleotide sequence of the 5\'-flanking region of the human *NPPB* gene. The nucleotide sequences are numbered (left) with respect to the major transcription start site (designated +1; *closed triangle*). *Boxe*s, the primers (PCR-SSCP); *double underlining,* the primers (sequence and genotyping); *overlining,* ATG initiation codon; *Underlining,* the variable number of tandem repeat (VNTR) consists of the 4 nucleotides (TTTC). This figure shows the 11 repeat types. **B**: Nucleotide sequence of the 11 and 16 repeat allele.](ijmsv04p0146g02){#F1}
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